Actelion included on Swiss Market Index
This article was originally published in Scrip
Executive Summary
Actelion's shares have begun trading on the Swiss Market Index (SMI), the Swiss blue-chip index. Actelion went public eight years ago and has two marketed products: Tracleer (bosentan) for the treatment of pulmonary arterial hypertension and Zavesca (miglustat) for the treatment of mild to moderate type I Gaucher's disease. The SMI represents around 85% of the free-float capitalisation of the Swiss equity market.